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President-REDVERS IRONSIDE, F.R.C.P. [April 5, 1956] DISCUSSION ON MYASTHENIA Dr. J. Hamilton Paterson (London): Credit for the first description of myasthenia gravis is often given to Wilks (1877) of Guy's Hospital and to Erb (1879) , though Guthrie (1903) pointed out that Thomas Willis had described a patient with myasthenia gravis, judging by an account in his "De Anima Brutorum", published in Oxford in 1672 and translated into English by Pordage after Willis' death. Erb incidentally described the condition in 3 patients, 2 of whom he had seen in Friedreich's clinic at Heidelberg. He remarked on the liability of bulbar musculature to become involved, the frequency with which ptosis occurs and the progression of the condition by remission and relapse with a tendency to terminate in sudden death. In 1887 Eisenlohr and Oppenheim described single cases, as did Shaw three years later. They were concerned in differentiating myasthenia gravis from Duchenne?s bulbar palsy as is indicated by the title to Shaw's paper in Brain in 1890-"A case of bulbar paralysis without structural changes in the medulla".
In 1893 came Goldflam's classical contribution. His close symptomatological analysis left little to be added subsequently. He pointed out that myasthenics became progressively weaker as the day advanced. He described the characteristic features of myasthenic weakness, noting that 20-30 movements involving affected muscles might reduce their voluntary response to zero. He stated that daily remissions and relapses were common but indicated that the former could last for up to four years. It was Jolly, however, who coined the current name for the condition for in 1895 he published his experiences with 2 patients under the title of "Myasthenia Gravis Pseudoparalytica", and described the myasthenic reaction obtained by repeated faradic stimulation of affected muscles. It is interesting to note that Jolly considered that myasthenia gravis was due to an abnormal condition of the muscles themselves.
By the time of Campbell and Bramwell's comprehensive review in 1900 there were some 60-70 cases on record. They noted that the muscles most likely to be implicated were those normally used most constantly, that weakness and even actual paralysis might persist after prolonged rest, and also that Jolly's myasthenic reaction to faradism might be unobtainable or but a passing manifestation. They considered that atrophy of affected muscles was altogether exceptional though they noted that it had been occasionally described. Campbell and Bramwell concluded that myasthenia gravis was probably due to a toxin acting upon either the axons of the motor nerves or their end-plates and interfering with their functional activity without causing structural changes.
Subsequently it became generally recognized that so-called myasthenic fatigability and persistent weakness were separate but often co-existent phenomena. It also became evident that actual muscle wasting was not so rare as Campbell and Bramwell had maintained; that cardia,c muscles might on occasions be involved was suggested by some authors, while others showed that definite histological changes in muscle were occasionally to be found. Again, following on Weigert's discovery in 1901 of a thymoma in a patient dying from myasthenia gravis the importance of the thymus in the condition became increasingly evident.
In 1934 came Mary Walker's "scoop", the demonstration of the efficacy of physostigmine in the treatment of myasthenia gravis. This coincided with Dale and Feldberg's discovery OCTOBER of the role played by acetylcholine in transmission at motor nerve endings in voluntary muscles, for they gave a preliminary report of their work at the May meeting of the Physiological Society in the same year. It is not surprising that those who held that myasthenia gravis was due to some defect in transmission at the myoneural junction were not slow to relate these two discoveries. Thus next year we find Hamill and Walker suggesting that the effect of neostigmine "seemed explicable on the hypothesis that in myasthenia gravis there is defective production at the nerve terminals of acetylcholine or some allied substance, and that under the influence of the drug destruction of this substance is delayed". From this approach stems one of the two main trends in research into the condition in the last two decades-that concerning the myoneural junction. The second trend-the role ofthe thymus in myasthenia gravis-received its main impetus at the hands of those who have demonstrated the undoubted value of thymectomy in the treatment of the disorder, but it derives from older considerations, as has been seen. Diagnosis
Prior to the advent of neostigmine the diagnosis of myasthenia gravis could naturally be made on clinical grounds only, though thedemonstration of Jolly's myasthenic reaction was occasionally of help. After 1934, however, the value of a test dose of neostigmine soon became apparent and a prompt response to this drug is considered diagnostic particularly if the clinical features of the case do not conflict with the diagnosis. Of course, on occasions clinically typical examples of the condition do not appear to respond to neostigmine; commonly in advanced cases, for example, there may develop a relative or seemingly absolute resistance to the drug. Again, but rarely, the clinical picture may be typical of myasthenia gravis yet the response to neostigmine is never other than equivocal. Rowland (1955) has recently described a good example of this state of affairs. On the other hand an alternative diagnosis may be considered if, despite myasthenic weakness responding to neostigniine in greater or lesser degree, there are clinical features which do not accord with the classical descriptions of myasthenia gravis, or if there is evidence to suggest the presence of some other disorder.
Myasthenia in Other Conditions
(1) Thyroid disorders.-There are quite a number of accounts in the literature concerning patients, most of whom were women in the middle decades of life, who apparently had classical myasthenia gravis as well as thyrotoxicosis. Millikan and Haines (1953) have reported 25 such cases, in the majority of which hyperthyroidism developed before or simultaneously with the onset of myasthenia. They estimated that approximately 5 % of myasthenics might also develop thyrotoxicosis. Treatment of the latter seemed to relieve the myasthenia in some instances but in others it had no effect. On occasions, a so-called "seesaw" relationship between hyperthyroidism and myasthenia has been described in that the latter is apparently relieved by the onset of the former only to become worse when the thyrotoxicosis is treated. There have also been reports indicating that the weakness of chronic thyrotoxic myopathy may on occasions respond to neostigmine though, as McEachern and Ross (1942) pointed out, the myasthenic weakness in these patients is confined to the trunk and limbs, sparing muscles innervated by cranial nerves. Again there is that rare but dangerous condition termed by some "acute thyrotoxic bulbar palsy" or "myopathy", and by others "acute thyrotoxic encephalomyopathy". Laurent (1944) and Sheldon and Milnes Walker (1946) among others have reported examples responding to neostigmine, and, in the case reported by the latter authors, the trouble cleared up completely after thyroidectomy. It is not surprising that some uncertainty exists as to whether such patients have myasthenia gravis complicated by thyrotoxicosis or what has been termed thyrotoxic myasthenia.
(2) Polymyositis and related states.-Muscle weakness with or without demonstrable atrophy is, of course, the outstanding feature of the condition currently referred to as polymyositis but it is also encountered in the related states of dermatomyositis and systemic lupus erythematosus. This weakness on occasions responds to neostigmine. Reese and Harman (1954) and Christensen and Levison (1950) among other authors have noted this in relation to polymyositis. Bonduelle, Bouygues and Coulon (1955) describe two patients with dermatomyositis who had marked muscle weakness with fatigability of a myasthenic character which responded dramatically to neostigmine and Harvey et al. (1954) .record neostigmine-responsive muscle weakness in systemic lupus erythematosus. It is interesting to note that Bonduelle, Bordet, et al. (1955) have also studied a patient with polymyositis who was found at autopsy to have a thymoma. In this instance neostigmine had no effect.
Here again the issue is somewhat complicated, for Stortebecker (1955) and others have described histological changes in the muscles of patients with apparently uncomplicated ,g 47 Section of Neurology 791 myasthenia gravis which are indistinguishable from those seen in polymyositis and its related disorders.
(3) Carcinomatous myopathy.-Henson, Dorothy Russell and Marcia Wilkinson (1954) in their comprehensive review of carcinomatous neuropathy and myopathy recorded several cases with muscular fatigability and weakness responding in varying degree to neostigmine. Heathfield and Williams (1954) concurrently described another patient whose initial complaint of weakness of hip flexors and thigh muscles improved dramatically when he was given neostigmine, though he showed some features, notably loss of knee and ankle jerks, which are not typical of myasthenia gravis. Anderson, Churchill-Davidson and Richardson (1953) , Mackenzie (1954) , Shafar (1954) and Borelli and Kean (1954) have also reported patients with bronchogenic carcinomata who had myasthenia responding readily to neostigmine. A link between this group and the previous one is suggested by the known association of dermatomyositis with malignant disease though apparently none of the patients described in these reports showed any skin changes of note.
(4) Nutritional disorders.-In 1947 Denny-Brown drew attention to several rather obscure syndromes with myasthenic features which have been described in individuals suffering from prolonged dietary deficiency. A remarkable outbreak of this kind was recorded by Musselman (1945) and Katz (1946) in American prisoners in Cabanatuan. A group of patients, recovering from dengue in 1944, developed ptosis, diplopia and weakness of neck and facial muscles followed by dysarthria and dysphagia. The extremities were also involved in some. The condition responded promptly to restriction of salt intake and the addition of protein, potassium chloride and thiamine to their meagre rations. Katz also mentioned another group of war prisoners in the same camp who earlier had developed flaccid weakness of the arms and legs without cranial nerve symptoms. Their weakness responded rapidly to neostigmine.
Denny-Brown noted that a rather similar outbreak had been described in Japan in 1896 by Miura. This was known as "Kubisagari"-literally "one who hangs his head".
Histological Changes in the Muscles in Myasthenia Gravis The literature on this subject is, in fact, quite considerable. It is generally assumed that Weigert was the first to describe in 1901 the lesions which Buzzard (1905) later called lymphorrhages. .However, their prior description has been attributed to Glockner (1896) of Switzerland. Weigert (1901) was the first to associate myasthenia with a thymoma although he thought that the lymphorrhages he found were metastases from the thymic tumour. Subsequently lymphorrhages came to be thought pathognomonic of myasthenia gravis though more recently they have been demonstrated in a variety of disorders including Addison's disease, thyrotoxicosis and rheumatoid arthritis. However, Querido (1929) showed that these focal cellular accumulations in the muscle of myasthenics were not always exclusively composed of lymphocytes. His autopsy findings in an apparently typical case of myasthenia gravis were microscopically characterized by degeneration of myocardial and skeletal muscle with infiltration of these muscles by perivascular foci of leucocytes, lymphocytes, plasma cells and fibroblasts, associated with a marked increase in fibrous tissue in relation to these foci.
He also found similar cellular accumulations in the liver, lungs and kidneys. Querido suggested that myasthenia gravis was a general vascular disease which could be defined pathologically as a chronic proliferating perivasculitis.
There have recently been quite a number of similar reports of muscle fibre degeneration of varying severity associated with cellular infiltration of an inflammatory character involving both voluntary and cardiac muscle. These include Professor Dorothy Russell's important contribution in 1953. It will be recalled that her findings were based on an examination of 8 consecutive patients, 4 of whom had thymomas. She classified her histological findings in the muscles into three types. In type I, representing the most acute changes, fibres undergo necrosis with resulting inflammatory cellular reaction and then disappear. Type II changes are characterized by a progressive atrophy of individual fibres associated with the formation of lymphorrhages in the later stages, while in type III only simple atrophy affecting single fibres or groups of fibres, having a different character to type II changes, is seen. Professor Russell found these three types of lesion to occur in a given striated muscle either singly or in combination. Often they were quite striking in the musculature of the tongue, palate, pharynx and upper cesophagus of patients who had bulbar myasthenia. Furthermore, she noted quite a close association between the histological changes and the clinical evidence of functional impairment, particularly in regard to the more severe abnormalities. The presence or absence of a thymoma did not appear to affect the issue, however. The myocardium was frequently involved, type I changes being found in 3 of the 6 cases in which the heart was examined. Professor Russell concluded that these histological features, while not peculiar to or diagnostic of myasthenia gravis, were closely related to the muscular wasting and weakness encountered in her patients. Mendelow and Genkins (1954) described similar histological changes in 6 of 12 consecutive autopsies on myasthenics with or without thymomas. Myocardial changes of all degrees of severity up to marked necrosis were found in these 6 patients and were paralleled by similar changes in striated muscle elsewhere. All 4 patients with thymomas had myocardial lesions. Stortebecker (1955) has recently reviewed his muscle biopsy findings in 13 patients with myasthenia gravis. 6 of the 13 showed pathological features characterized by a varying degree of muscle atrophy with perivascular round cell infiltrations. He considered that these appearances were indistinguishable from those of polymyositis-a point to which reference has already been made.
The development by Coers of a new biopsy technique of vital staining with methylene blue has afforded a new histological approach to the subject and has led to the demonstration of changes in the nerve endings in muscle which cannot be detected by the usual staining methods. Woolf et al. (1956) have recently studied a patient with myasthenia gravis in this way. A biopsy examination of one of the deltoid muscles showed changes in muscle fibres corresponding to Professor Russell's types II and III. The application of Coers' technique demonstrated a striking abnormality of the sub-terminal motor fibres, the terminal arborizations and the terminal expansions of the intramuscular nerve endings. However, these changes are not pathognomonic of myasthenia gravis, and in other cases examined by this method the nerve endings have appeared normal (C6ers and Woolf, 1954) . Woolf and his colleagues considered that in their patient the abnormalities may have depended on loss of contact of the nerve endings with the degenerated muscle fibres. This would explain why they have not been constantly found for it must not be forgotten that many cases of myasthenia gravis have been reported in which no histological changes in the clinically affected muscles have been noted.
Most of the available accounts of histological changes in the muscles of myasthenics have been based on autopsy examinations and such scanty information as they contain in regard to the neostigmine responsiveness of these muscles is often only related to the patients' terminal state. When accessible muscles are clinically involved more attention might profitably be paid to their histological appearances in life as seen in biopsy specimens. Such research might help explain why some myasthenic muscles respond initially to neostigmine, only to become resistant to this drug later on and why, on occasions, permanent weakness with or without demonstrable atrophy ensues.
Conclusion
Throughout this paper I have perhaps referred to myasthenia gravis as if it were a disease entity clearly to be differentiated from those other disorders which have been mentioned in which myasthenic weakness may be prominent. This differentiation, however, clearly breaks down at many points. Several writers have emphasized recently that myasthenia gravis is not an entity as such but is a syndrome of varied etiology. Our ignorance as to its causation does not allow of the assumption that the same physiological disturbances are operative in every case. To attempt any elaborate classification without knowledge of the cause or causes of the syndrome will only add to the present confusion.
Dr. H. C. Churchill-Davidson (Department of Anaesthetics, St. Thomas' Hospital, London): For many years the mechanism at fault in myasthenia gravis has fascinated both clinicians and research workers alike. It is generally agreed that the muscle weakness so characteristic of myasthenia shows many features that strongly resemble the interference with neuromuscular transmission due to d-tubocurarine. This has led many authors to search for the presence of a curare-like substance in either the thymus gland or the circulation of myasthenic patients. However, there are certain criteria that must be fulfilled if any such substance is to be deemed worthy of the term "curare-like". First, the neuromuscular block must be readily reversed by an anti-cholinesterase such as neostigmine or Tensilon; secondly, slow rates of stimulation must be better able to traverse the neuromuscular block than fast ones; and finally, although the muscle fibre may fail to respond to indirect 5timulation through its motor nerve, it must at all times remain capable of contracting on direct stimulation. 'Up to the present time no extract from either thymic tissue or the serum of myasthenic patients has been found that can fulfil more than one of these criteria.
Much of the research into this condition has centred around attempts to assess the effect of acetylcholine on myasthenic muscle, but the extremely short duration of action of this substance has made the results difficult to determine. In 1948, however, Paton and Zaimis introduced a substance-decamethonium iodide (C.10)-which acted in a similar manner to acetylcholine but had the advantage that it was not rapidly destroyed by cholinesterase. The prolonged activity of this new drug made it possible for the first time to study the response of both normal and myasthenic muscle to an "acetylcholine-like" substance, and thus to remodel our theories of the underlying fault in this disease.
Before proceeding to a discussion on the significance of these results it is important to emphasize the general assumptions that are made regarding neuromuscular transmission in normal subjects. In 1936 Dale, Feldberg and Vogt initiated the theory of a chemical transmitter substance-acetylcholine-as responsible for bridging the gap between nerve and muscle. To date this has withstood the test of time. Briefly, when a stimulus reaches the end of a motor nerve, acetylcholine molecules are released. These rapidly pass to the receptor protein on the adjacent part of the muscle fibre (termed motor end-plate) and create a change in the electrical polarity-namely, depolarization. Depolarization of the endplate is the signal that triggers off a similar response which passes in both directions along the muscle fibre and is followed by a mechanical contraction. With acetylcholine the duration of depolarization of the end-plate, in vivo, to a single stimulus is but a fraction of a second, but after the administration of decamethonium the end-plate remains depolarized for ten to twenty minutes or longer. In other words, a depolarization block is present. d-Tubocurarine, on the other hand, prevents the acetylcholine molecules from gaining access to the receptor protein (end-plate), and thus blocks transmission of nerve impulses (nondepolarization block) until such time as the concentration of acetylcholine is permitted to accumulate-as occurs following the adminstration of an anti-cholinesterase or when finally the curare molecules are washed away into the general circulation.
There are, therefore, two fundamental types of neuromuscular block in man: depolarization block caused by acetylcholine and C.10 and non-depolarization block caused by d-tubocurarine. An essential difference between these two types of block is that an anti-cholinesterase-neostigmine or Tensilon-increases or does not alter a depolarization block, but will reverse one due to d-tubocurarine.
About six years ago, my colleague, Dr. A. T. Richardson, and I started to determine the effect of C.10 on the muscles of both normal and myasthenic subjects. At the outset we satisfied ourselves that our method using both electromyographic and volitional measurements gave consistent results in a group of normal volunteers.
Whenidiscussing the response of myasthenic patients to C.10 it is important to emphasize that there is a wide variation in the response of different muscle groups in any one subject. Notwithstanding this, however, two typical types of reaction may be high-lighted. First, there are those muscles which are resistant to the depolarizing action of C.10 and can tolerate doses three or four times that required to paralyse the muscles of a normal subject completely. At the other extreme, the muscle fibres rapidly become paralysed on the intravenous injection of decamethonium, but-in complete contrast to the normal subject-this weakness can rapidly be reversed by the administration of an anti-cholinesterase substance such as neostigmine or Tensilon. Briefly, these muscles first show some fleeting signs of a depolarization block before changing to that of the non-depolarization type-the so-called "dual response" (Churchill-Davidson and Richardson, 1953) . This dual type of neuromuscular block is of particular importance because it can be seen in certain species of animals (Zaimis, 1953) . For example, the muscles of the cat respond to C.10 in a similar manner to those of a normal subject, whereas the muscles of a myasthenic react like those of a dog or a monkey.
Further experimentation revealed that although decamethonium produced a dual type of response in myasthenic patients, it could be recovered unchanged from the urine of these patients. On the basis of these results we put forward the theory that the weakness of myasthenia gravis was not due to a circulating curare-like substance but to an alteration in the response of the motor end-plate to acetylcholine or one of its breakdown products (Churchill-Davidson and Richardson, 1953) .
In 1955 Grob, John and Harvey published their findings on the effects of the intra-arterial injection of acetylcholine. Immediately following the injection there is a brief failure of muscle activity lasting about thirty seconds. About a minute after recovery has taken place the muscle fibre begins to show a secondary failure which, though not so severe, may persist for thirty minutes or -longer. They found that the effect of the intra-arterial injection of choline-a breakdown product of acetylcholine-was identical with this secondary failure. Furthermore,.although the injection of neostigmine enhanced the initial depression caused by acetylcholine in both normal and myasthenic patients, it increased the secondary failure in normal subjects but reversed the weakness in myasthenics. The inference is drawn, therefore, that acetylcholine acts in cases of myasthenia in two phases-an initial depolarization followed rapidly by a more prolonged non-depolarization block due to its breakdown product, choline. In other words, the dual response.
These results are complementary to our own using decamethonium in myasthenia, and together they provide convincing evidence that the mechanism at fault is an alteration in response of the motor end-plate. I should like now to consider the value of decamethonium as a clinical test for the presence of the myasthenic syndrome. The basis of the test is to stimulate the ulnar nerve supramaximally at a rate of ten times per second and then to record the resultant integrated action potential on a cathode-ray oscillograph. In normal subjects a total dose of 2-5 mg. is sufficient to reduce the height of the action potential to one-fifth of its normal size, whereas in the myasthenic patient there is a negligible change.
If the myasthenic weakness is generalized the administration of decamethonium may so increase the paresis that it is no longer possible to give the full test dose. However, in such an instance 10-15 mg. of Tensilon intravenously brings about an almost instantaneous but temporary reversal of the weakness in cases of myasthenia.
It is important to emphasize that in our series of 42 cases a positive response to this test is specific for myasthenia gravis. We have investigated a number of cases in which the diagnosis of myasthenia was difficult when based solely on clinical grounds or on the response to neostigmine: in each of these cases the response to C.10 has made it possible to arrive at a definite conclusion. As a diagnostic test it is superior to neostigmine because some cases may fail to show a convincing recovery with the latter drug; it is of particular value, however, in distinguishing an hysterical from an early myasthenic weakness.
Again, this test has been found to be useful in investigating other allied conditions with a muscle weakness which has been reported at various times to respond to neostigmine. For example, we have examined 7 cases of dermatomyositis and 2 cases of thyrotoxic myopathy but failed to find a positive response. However, in 3 cases of carcinoma of lung and 1 case of thyrotoxicosis-each without a skin rash or wasting-we were able to detect the presence of this myasthenic change. Clearly much more work needs to be done before any conclusions can be drawn from these results.
The value of thymectomy in the treatment of this condition is controversial. However, we have examined 5 patients before operation and for periods from three and a half to five years after the removal of the thymus gland. Each case gave a positive result pre-operatively and despite the fact that 2 of these cases are now in a complete remission and must be classified as a clinical cure, the positive response has persisted in every patient. Furthermore, in 15 other cases-tested after thymectomy had been performed-the response was positive. There still remain many features of the dual response in myasthenia that require further study. For example, is this change present in close relatives and offspring? Again, does a patient who has once shown a positive response ever revert to normal?
Reviewing our results to date using decamethonium we are tempted to speculate on the natural history of myasthenia. It would seem most convenient to divide the response into three stages. The first is the resistant phase wherein the muscle fibre can withstand far larger doses of decamethonium than normal without undergoing depolarization. Such a response cannot be recognized clinically because these muscle fibres do not show any signs of weakness. Examples of this group are best seen in the limb muscles of cases of ocular myasthenia. In the second group are those muscle fibres which show evidence of the dual response. The onset of this phase is characterized by the appearance of clinical weakness and there is evidence that the response of a particular group of muscles can freely interchange between these two phases. As yet, however, we do not have evidence that a muscle fibre in the resistant phase can return to a normal response. The third stage is termed refractory because here the muscle fibre fails to respond to neostigmine and wasting may become a prominent feature. The best examples of this group are usually to be found in cases of long-standing myasthenia, but this does not preclude the possibility of its occurrence in those patients with a recent history of muscle weakness. The problem of the underlying mechanism of myasthenia still remains, but the conception of an alteration in the response of the motor end-plate can explain almost all of the clinical features. The fact that a similar type of response to decamethonium in myasthenia can be found in certain species of animals gives us hope that it will not be long before someone can demonstrate the cause of this change and that the secret of myasthenia will then be revealed. The Value of Thymectomyl Though seventeen years have passed since Blalock re-awakened interest in the role of thymectomy in myasthenia gravis, the value of the operation is still debated. Dr. E. A. Carmichael suggested that I should make an independent assessment of the National Hospital series. Sir Geoffrey Keynes invited me to extend the survey to include all patients operated on by him at New End and St. Bartholomew's Hospitals. As a control series those patients attending the National Hospital since 1934 with a diagnosis of myasthenia gravis were reviewed.
1A more complete account will be published elsewhere.
The diagnosis was made by the staff of the National Hospital and by other members of the Association of British Neurologists. I examined the majority of the survivors of both series; a few patients were questioned by post. I have adopted the role of devil's advocate to avoid the chance of introducing a bias favourable to the operation. This should be borne in mind when assessing the figures to be presented as they deliberately show the operation in what I believe to be the worst light. Patients were classified at follow-up examination according to the following criteria which are based on those used by Ross (1952) . The essential feature is an assessment of change of status from the pre-operative state or the state on first admission to hospital in the control cases. Hence a patient with little disability does not qualify for a high category if this state is not significantly better than at the datum point. In case of doubt a patient was assigned to the lower category. It will be seen that any bias has been deliberately applied in a sense adverse to the operation. (c) Worse. Altogether 404 cases were available for study. Of the 270 female cases 11 % had thymic tumours, and 13 % of the 134 males. The higher age of onset and poor prognosis of these patients was confirmed and they will not be further considered here. The non-tumour cases (241 females and 116 males) showed a remarkably "normal" distribution curve for the age of onset which does not suggest that myasthenia gravis was diagnosed in a heterogeneous collection of unrelated diseases.
The operated series (182 females, 76 males) showed certain differences from the control series (59 females, 40 males). The former contained a preponderance of females at all age groups, the sex ratio varying from 4 5 : 1 in cases starting in the first decade to 1 1 : 1 in cases starting in the fifth decade. In the control series the sex ratio was even except in the 20-40 age group where females were in excess, and in the sixth decade where males outnumbered females. The two series were comparable for patients starting in the third decade and so the results of the whole comparison have been checked in this group but otherwise it has been thought advisable to compare the sexes separately. There was a statistically significant difference in the mean age at onset between the operated and not-operated series (the latter being nine years older at onset in both sexes). The standard error of the mean of the unoperated series was, however, much greater than that of the operated series. Possibly the early history of the thymectomy series has been more fully documented or the size of the sample is too small in the not-operated series. The mean survival from the first symptom was the same in the two series-females 13f0 and 14-7 years, males 12f5 and 12-4 years (the operated series is the first figure) .
Results
The percentage of each series in each category at follow-up is shown in Table I differences are apparent between the operated and not-operated series: (i) in each sex all survival categories are increased and the deaths from myasthenia are reduced, (ii) there is no marked difference between the sexes in the operated series. The significance of these conclusions is tested in Tables II and III. The higher proportion of patients in the A+B category, and the decrease in deaths due to myasthenia are greater than can be explained by chance in the female sex. This level of statistical significance is not reached in the males but the trend is the same (Table II) . Slightly more women than men are in category A +B after operation and fewer women than men died of myasthenia. The analysis (Table III) shows that this could have occurred by chance but it should be noted that this represents a reversal of the trend found in the un-operated series where females had a slightly poorer prognosis than males. These data may be summarized in the statement that the status at follow-up examination of the two sexes is not significantly different but that the females have more to gain from operation-a prognosis slightly poorer than the male in the not-operated series being changed to a slightly better prognosis in the operated series, the change being greater than can be explained by chance. This conclusion reconciles the apparently conflicting statements of Keynes (1949) and Schwab and Leland (1953) .
The extent of the improvement due to thymectomy may seem disappointing. It must be re-emphasized that this represents the minimum estimate of the distribution of categories.
There are fewer deaths due to myasthenia (and indeed fewer deaths, even including the operative risk) and the survivors show a general "shift to the left". It must not be forgotten that the method of assessment makes little allowance for the magnitude of this shift. It does not give any indication of the patient, bedridden for years, who becomes able to resume a normal life after his thymus is removed. This could be indicated only by a method of comparison of grades of severity. This was not used in the present study owing to its retrospective nature and because of the difficulty of maintaining standards over the long periods involved. Further analysis shows that the age of onset does not differ significantly in the different categories, but Keynes' (1949) statement that the best results are obtained in patients with a short pre-operative duration of myasthenia is confirmed (though statistically significant in females only). The follow-up period is comparable for all categories and there is no significant difference in their pre-operative requirements for Prostigmin.
Possible factors in the sex difference described above may be (i) thyroid abnormality was twice as common (18 %) in women as in men (60 % of the abnormalities noted were nontoxic); (ii) involvement of bulbar muscles at the onset was twice as common in women and initial weakness restricted to the extra-ocular muscles was more common in men; (iii) myopathic changes were twice as common in men as in women. Electromyographic studies were presented to show that myopathic changes are common in myasthenia gravis without wasting and that the wasted muscles show changes indistinguishable from myositis. Lundervold's (1954) observation that myasthenic "fatigue" may involve derecruitment of motor units rather than decrement of individual units was confirmed.
It was suggested that the evidence of electromyography and of histology as described by Dr. Hamilton Paterson shows that the pathological changes of myasthenic muscle are not confined to the neuromuscular junction.
